EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer

Keisuke Shigeta iD, Masanori Hasegawa iD, Takako Hishiki, Yoshiko Naito, Yuto Baba, Shuji Mikami, Kazuhiro Matsumoto, Ryuichi Mizuno, Akira Miyajima, Eiji Kikuchi, Hideyuki Saya, Takeo Kosaka iD und 1 weitere

The EMBO Journal · 2023

DOI: 10.15252/embj.2022110620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The EMBO Journal, 2023. Verfasst von Keisuke Shigeta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Grant‐in‐Aid for Scientific Research of Japan, Japanese Foundation for Research and Promotion of Endoscopy Grant, Keio Medical Association Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsHumansCell Line, TumorDrug Resistance, NeoplasmGemcitabineGlycolysisHypoxia-Inducible Factor 1, alpha SubunitPentose Phosphate PathwayIsocitrate Dehydrogenase

Stichwörter der Autor:innen

chemoresistancehypoxia-inducible factor-1αisocitrate dehydrogenase 2metabolomic reprogrammingurothelial carcinoma

Substanzen

GemcitabineHypoxia-Inducible Factor 1, alpha SubunitIDH2 protein, humanIsocitrate DehydrogenaseHIF1A protein, human

Autor:innen und Institutionen

  • Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Urology, Tokai University School of Medicine, Tokyo, Japan.
  • Department of Clinical and Translational Research center, Keio University School of Medicine, Tokyo, Japan.
  • Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan.
  • Division of Pathology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan.

ORCID-Profile: Keisuke Shigeta, Masanori Hasegawa, Takeo Kosaka, Mototsugu Oya

Förderung

  • Grant‐in‐Aid for Scientific Research of Japan
  • Japanese Foundation for Research and Promotion of Endoscopy Grant
  • Keio Medical Association Grant
  • Keio Medical Otsuka Fumon/Fusako Fellowship Grant
  • Keio University Graduate School Doctoral Program Grant

Zitieren

APA

Shigeta, K., Hasegawa, M., Hishiki, T., Naito, Y., Baba, Y., Mikami, S., Matsumoto, K., Mizuno, R., Miyajima, A., Kikuchi, E., Saya, H., Kosaka, T., & Oya, M. (2023). IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer. The EMBO Journal. https://doi.org/10.15252/embj.2022110620

Vancouver

Shigeta K, Hasegawa M, Hishiki T, Naito Y, Baba Y, Mikami S, et al. IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer. The EMBO Journal. 2023. doi:10.15252/embj.2022110620

BibTeX
@article{Shigeta2023,
  author = {Shigeta, Keisuke and Hasegawa, Masanori and Hishiki, Takako and Naito, Yoshiko and Baba, Yuto and Mikami, Shuji and Matsumoto, Kazuhiro and Mizuno, Ryuichi and Miyajima, Akira and Kikuchi, Eiji and Saya, Hideyuki and Kosaka, Takeo and Oya, Mototsugu},
  title = {IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer},
  journal = {The EMBO Journal},
  year = {2023},
  doi = {10.15252/embj.2022110620}
}
Kostenlos starten →